Completed Clinical Trials
Centricity Research has proudly participated in many trials that have the potential to impact the lives of hundreds of thousands of people around the globe. Below is a list of some of our completed trails.
Centricity Research has completed 6 clinical trials focused on slowing down the progression of the disease in those with different stages of Alzheimer’s disease (prodromal, mild, moderate).
Centricity Research has completed a clinical trial focused on the prevention of Alzheimer’s Disease for patients not showing any signs or symptoms of memory loss, who may have an increased risk of developing Alzheimer’s based on their APOE genetic status.
Centricity Research has completed over 10 clinical trials focused on improving cognition in those with different stages of Alzheimer’s disease (prodromal, mild, moderate).
Centricity Research has completed 3 clinical trials focused on improving neuropsychiatric symptoms in those with different stages of Alzheimer’s disease (mild, moderate, severe).
Frontotemporal dementia is dementia resulting from the progressive degeneration of the temporal and frontal lobes of the brain. Centricity Research was involved in a clinical trial for patients diagnosed with frontotemporal dementia. The trial compared an investigational medication vs placebo, analyzing the cognitive and functional abilities of the participants throughout trial participation.
Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Centricity Research has been involved in 2 clinical trials for children ages 7-17 with a diagnosis of Tourette’s Syndrome, who had tic symptoms that were severe enough to interfere with their normal routines. The investigational medication being studied was Aripiprazole. The main outcome being measured was a change in score on the Yale Global Tic Severity Scale, with close monitoring of all safety assessments such as vital signs, ECGs, weight, and bloodwork.
Opioid Induced Constipation
Opioid use carries side effects including drowsiness, nausea, slower breathing, general depression of the respiratory system and constipation, or opioid-induced constipation (OIC). Centricity Research was involved in a clinical trial researching an investigational medication for the treatment of opioid-induced constipation for those taking opioids for chronic non-cancer pain. The main focus of the trial was the safety and tolerability of the study drug vs placebo, based primarily on the number and type of adverse events which occurred during study participation.
Attention Deficit Hyperactivity Disorder (ADHD)
ADHD is a common behavioral disorder that affects an estimated 8% to 10% of school-age children. Centricity Research was involved in a clinical trial comparing two already-marketed medications, Vyvanse and Concerta, in adolescents ages 13-17. The participants received vyvanse, concerta, or placebo once a day for 6 weeks. The main outcome was an analysis of ADHD symptoms between the three treatment groups.
Depression is a mental disorder that can affect anyone, with nearly 4 million Canadians suffering from depression annually. Centricity Research has been involved in 6 clinical trials focused on major depressive disorder. 5 of these clinical trials were focused on researching new investigational medications in those who had experienced inadequate responses to other antidepressant therapies. These clinical trials focused on analyzing depression symptoms in those taking their prescribed antidepressant therapy and placebo vs those taking their prescribed antidepressant therapy and the investigational medication. The 6th clinical trial was focused on the relationship between an already-marketed antidepressant Vortioxetine and workplace productivity in those with major depressive disorder.
Obsessive Compulsive Disorder (OCD)
Obsessive-Compulsive Disorder (OCD) is a chronic and sometimes disabling condition affecting from 1% to 3% of the general population around the world. Centricity Research has been involved in 1 clinical trial researching a new potential treatment option for OCD. This 16-week trial compared 2 different doses of an investigational medication to a placebo. Participants had to be receiving an SSRI medication (the typical treatment for OCD symptoms) at the beginning of the trial and remain on this medication for the duration of the trial. The trial was designed to assess changes in OCD symptom severity.
Bipolar Disorder, also known as manic-depressive illness, is a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks. Centricity Research has been involved in 2 clinical trials focused on Bipolar Disorder. These clinical trials recruited participants with Bipolar Disorder Type I. It compared two different doses of the injectable form of Aripiprazole to placebo, as monthly injections. The trials were designed to compare the time from entering the study to the onset of any mood episode (manic or depression) in participants receiving the injectable aripiprazole vs placebo.
Down syndrome is a chromosomal disorder caused by an error in cell division that results in an extra 21st chromosome. The condition leads to impairments in both cognitive ability and physical growth that range from mild to moderate developmental disabilities. Centricity Research has been involved in 3 clinical trials focused on Down syndrome. One of these trials was focused on assessing the suitability of several different assessments to measure function, cognition, and IQ in participants with Down syndrome, while the other two trials were focused on how a new investigational treatment was believed to improve cognitive abilities compared to placebo in participants with Down syndrome.
Fibromyalgia is a syndrome that causes fatigue and widespread muscle pain throughout the body. Centricity Research was involved in a clinical trial for adults who suffered from pain associated with fibromyalgia. The trial was 13 weeks long and compared scores on daily pain assessments of those taking a new investigational treatment versus those taking pregabalin vs those taking placebo.
Female Sexual Dysfunction
Female Sexual Dysfunction is a persistent or recurring problem during one or more of the stages of sexual response, which causes distress or problems to the women. Centricity Research was involved in a clinical trial for pre-menopausal women experiencing hypoactive sexual desire. The trial compared an investigational medication vs placebo, administered as needed using a pre-filled subcutaneous auto-injector. The hypothesis was that the investigational medication would increase sexual desire, compared to a placebo.
Type 2 Diabetes Mellitus
Centricity Research was involved in a clinical trial evaluating the effects of an already-marketed medication Ticagrelor, compared to placebo, in the prevention of major cardiovascular events in patients with Type 2 Diabetes Mellitus who are at high risk of cardiovascular events but have not previously experienced a stroke or a heart attack.
Centricity Research was involved in a clinical trial, researching an investigational medication vs placebo in those with Osteoarthritis of the knee. The investigational medication being studied is designed to reduce inflammation and pain without causing gastrointestinal upset, which is a side effect of other commonly used arthritis treatments such as Naproxen.